Clinical Trial

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Study acronym: HARMONi-GI3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)
Protocol Amendment History 6 changes
notable Trial sites expanded: 140 -> 166 locations 2026-08-05
notable Trial sites expanded: 130 -> 140 locations 2026-07-07
notable Trial sites expanded: 91 -> 130 locations 2026-06-24
notable Trial sites expanded: 76 -> 91 locations 2026-06-23
notable Trial sites expanded: 54 -> 76 locations 2026-05-06
notable Trial sites expanded: 40 -> 54 locations 2026-04-07
Trial Details
NCT Number NCT07228832
Lead Sponsor Summit Therapeutics
Conditions Metastatic Colorectal Cancer (CRC)
Enrollment 600 participants
Start Date 2025-11-18
Primary Completion 2028-05-31 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-04